IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences

IDEAYA Biosciences (NASDAQ: IDYA) announced an Investor R&D Day in London on Monday, November 16, 2026, at 5:00 PM GMT, focused on MTAP/CDKN2A and KRAS development strategies in pancreatic cancer, including new preclinical data and combination approaches.

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced an Investor R&D Day in London on Monday, November 16, 2026, at 5:00 PM GMT, focused on MTAP/CDKN2A and KRAS development strategies in pancreatic cancer, including new preclinical data and combination approaches. The event will feature Dr. Frank McCormick of UCSF and requires advance registration for in-person and virtual attendance. IDEAYA will also participate in several major September 2026 healthcare and biopharma investor conferences in Boston and New York, with multiple fireside chats involving senior management and webcast access via the company’s investor website.

Argus Sep 1 session

-0.37% close to close Open Argus

Details

News Market Reaction – IDYA

On Sep 1, the day this news came out, IDYA closed 0.37% below the previous close.

Data tracked by StockTitan Argus for the Sep 1 session.

Key Figures

London Investor R&D Day: November 16, 2026 at 5:00 PM GMT Wells Fargo Conference: September 8, 2026 at 3:00 PM ET Cantor Conference: September 9, 2026 at 11:30 AM ET +3 more

London Investor R&D Day

November 16, 2026 at 5:00 PM GMT

London, United Kingdom

Wells Fargo Conference

September 8, 2026 at 3:00 PM ET

Boston, Massachusetts

Cantor Conference

September 9, 2026 at 11:30 AM ET

New York, New York

Citi Conference

September 10, 2026 at 1:40 PM ET

New York, New York

Morgan Stanley Conference

September 14, 2026 at 7:00 AM ET

New York, New York

Webcast replay period

30 days

Following the live events

Historical Context

5 past events · Latest: Aug 31

5 events

1. Aug 31

   FDA meeting update

   24h Move

   -0.1%

   FDA meeting informed planned Phase 3 registrational trial design for IDE849

2. Aug 28

   Inducement grants

   24h Move

   -4.0%

   Options granted to two newly hired employees under the inducement incentive plan

3. Aug 19

   Clinical collaboration

   24h Move

   +2.5%

   Genentech collaboration evaluated IDE892 with GDC-7035 in pancreatic cancer

4. Aug 04

   Second-quarter earnings

   24h Move

   +2.0%

   OptimUM-02 met its primary endpoint and NDA filing remained underway

5. Jul 31

   Inducement grants

   24h Move

   -2.5%

   Options granted to fourteen newly hired employees under the inducement incentive plan

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

mtap/cdkn2a, kras, tumor heterogeneity, adaptive plasticity

4 terms

mtap/cdkn2a medical

"management will discuss the company's MTAP/CDKN2A and KRAS development strategy"

mtap/cdkn2a refers to two neighboring genes on the same chromosome—MTAP and CDKN2A—that are often lost or altered together in certain cancers because of their close physical location. Investors encounter this term as a biomarker or genetic abnormality that can influence diagnosis, prognosis, and whether a tumor may respond to specific targeted drugs or diagnostic tests; think of it as a broken pair of switches that can change how cancer cells behave.

kras medical

"the company's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer"

KRAS is a gene that makes a protein acting like a switch to control cell growth; certain changes (mutations) can lock that switch on and drive uncontrolled cell multiplication, which is a common cause of many cancers. Investors care because drugs or tests targeting KRAS mutations can create large markets or avoidable risks depending on trial results and regulatory decisions, much like a key product feature deciding a gadget’s commercial success.

tumor heterogeneity medical

"designed to address tumor heterogeneity and adaptive plasticity"

Tumor heterogeneity describes the presence of different kinds of cancer cells within the same tumor or between tumors in the same patient, varying in genetics, behavior, and response to treatment. Like a neighborhood where houses differ in age, layout and occupants, this diversity can make it harder to design tests and drugs that work for all cells. For investors, heterogeneity matters because it affects how reliably therapies and diagnostics perform, influences clinical trial success, and helps determine a product’s market potential.

adaptive plasticity medical

"designed to address tumor heterogeneity and adaptive plasticity"

Adaptive plasticity is a biological property where cells, tissues, or whole organs change their structure or function in response to experience, injury, or environmental shifts. For investors, it matters because therapies, medical devices, or drugs that target or harness adaptive plasticity can alter recovery, disease progression, or treatment effectiveness, which affects clinical outcomes, regulatory approval odds, and market potential; think of it as the body rewiring or reshaping itself to cope.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and participation in September 2026 investor conferences.

IDEAYA Biosciences Investor R&D Day in London, United Kingdom
Monday, November 16th, 2026, at 5:00 PM GMT

• IDEAYA management will discuss the company's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer, including new preclinical data and rational combination strategies designed to address tumor heterogeneity and adaptive plasticity
• The event will feature Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center
• Advance registration is required for both in-person and virtual attendance. To register, please visit https://lifescievents.com/event/izl51pw/

Wells Fargo 21^st Annual Healthcare Conference
Tuesday, September 8th, 2026, at 3:00 PM ET, Boston, Massachusetts

• Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Eva Fortea-Verdejo, Ph.D., Executive Director, Equity Research, Biotechnology

Cantor Global Healthcare Conference 2026
Wednesday, September 9th, 2026, at 11:30 AM ET, New York, New York

• Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Li Watsek, Director, Biotechnology Analyst

Citi's 2026 Biopharma Back to School Conference
Thursday, September 10th, 2026, at 1:40 PM ET, New York, New York

• Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, and Joshua Bleharski, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst

Morgan Stanley 24^th Annual Global Healthcare Conference
Monday, September 14th, 2026, at 7:00 AM ET, New York, New York

• Fireside chat with Yujiro S. Hata, Chairman and Chief Executive Officer, hosted by Ryuk Byun, MD, Managing Director

A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding IDEAYA's plans and expectations concerning the timing, format, content and participation of IDEAYA and its management in the Investor R&D Day and investor conferences; the anticipated discussion of IDEAYA's MTAP/CDKN2A and KRAS development strategy in pancreatic cancer; the presentation of new preclinical data; the evaluation of rational combination strategies designed to address tumor heterogeneity and adaptive plasticity; the participation in and/or presentation at certain investor relations events; and the availability of live and archived webcasts of the events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 17, 2026.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski
Chief Financial Officer
investor@ideayabio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-london-investor-rd-day-and-participation-in-upcoming-september-2026-investor-conferences-302865528.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is IDEAYA Biosciences (NASDAQ: IDYA) holding its London Investor R&D Day in 2026?

IDEAYA Biosciences plans its London Investor R&D Day for Monday, November 16, 2026, at 5:00 PM GMT. According to the company, management will present MTAP/CDKN2A and KRAS pancreatic cancer strategies, including new preclinical data and rational combination approaches.

What topics will IDEAYA Biosciences cover at its November 16, 2026 London Investor R&D Day?

The London Investor R&D Day will focus on MTAP/CDKN2A and KRAS development strategy in pancreatic cancer. According to IDEAYA, management will highlight new preclinical data and combination strategies aimed at addressing tumor heterogeneity and adaptive plasticity.

How can investors attend IDEAYA Biosciences’ London Investor R&D Day and September 2026 conferences?

Attendance at the London Investor R&D Day requires advance registration for both in-person and virtual formats. According to IDEAYA, live audio webcasts for the R&D Day and September conferences will be available via the Investors/Events section of its website and/or conference hosts.

Which September 2026 investor conferences will IDEAYA Biosciences (IDYA) participate in?

IDEAYA will join the Wells Fargo, Cantor, Citi, and Morgan Stanley 2026 healthcare and biopharma conferences. According to the company, management will participate in fireside chats across Boston and New York between September 8 and September 14, 2026, with webcast access provided.

Who from IDEAYA Biosciences management will speak at the September 2026 investor conferences?

Chairman and CEO Yujiro S. Hata will speak at all listed conferences, with CFO Joshua Bleharski joining selected events. According to IDEAYA, the sessions are structured as fireside chats moderated by healthcare and biotechnology analysts.

Where can investors access replays of IDEAYA Biosciences’ September 2026 conference webcasts?

Replays will be available for 30 days following each live event. According to IDEAYA, investors can access these audio replays under the “Investors/Events” section of the company’s website or through the respective conference hosts’ platforms.